0000950170-22-023874 | 10-Q | XBRL Viewer

Print Document View Excel Document

Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Net loss	$ 8,205	$ 7,676	$ 7,784	$ 7,381	$ 4,199	$ 2,247	$ 23,665	$ 13,827
Net loss attributable to common stockholders, basic	8,205			7,381			23,665	13,827
Net loss attributable to common stockholders, diluted	$ 8,205			$ 7,381			$ 23,665	$ 13,827
Weighted-average number of common shares used in net loss per share, basic	11,827,663			8,159,044			10,451,300	3,994,784
Weighted-average number of common shares used in net loss per share, diluted	11,827,663			8,159,044			10,451,300	3,994,784
Net loss per share of common stock, basic	$ 0.69			$ 0.90			$ 2.26	$ 3.46
Net loss per share of common stock, diluted	$ 0.69			$ 0.90			$ 2.26	$ 3.46

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.

+ References + Details

Commitments and Contingencies - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Operating lease ROU asset	$ 0		$ 0		$ 0
Operating lease ROU liability	0		0		$ 0
Operating lease expense	$ 100,000		$ 100,000	$ 100,000
Maximum
Lessee, Lease, Description [Line Items]
Operating lease expense		$ 100,000

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income tax provision or benefit	$ 0	$ 0	$ 0	$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Subsequent Events - Additional Information (Details) - USD ($) $ in Millions	63 Months Ended
	Mar. 01, 2028	Oct. 21, 2022
Cambridge Lease Agreement \| Forecast
Subsequent Event [Line Items]
Rent payments	$ 4.0
Cambridge Lease Agreement \| Subsequent Events
Subsequent Event [Line Items]
Lease initial term		63 months
San Francisco Lease Agreement \| Forecast
Subsequent Event [Line Items]
Rent payments	$ 1.8
San Francisco Lease Agreement \| Subsequent Events
Subsequent Event [Line Items]
Lease initial term		63 months

Nature of the Business - Additional Information (Detail) $ / shares in Units, $ in Thousands			3 Months Ended						9 Months Ended
	Sep. 19, 2022 USD ($) $ / shares shares	Sep. 07, 2022	Sep. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) $ / shares shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from initial public offering \| $									$ 198,178	$ 0
Offering costs payable \| $									$ 1,419	0
Conversion of convertible preferred stock into common stock											49,624,187
Number of shares authorized for issuance			500,000,000						500,000,000		72,731,000
Par value of common stock \| $ / shares			$ 0.0001						$ 0.0001		$ 0.0001
Undesignated preferred stock, authorized			10,000,000						10,000,000		0
Preferred stock, Par Value \| $ / shares			$ 0.0001						$ 0.0001		$ 0.0001
Description of reverse stock split									Company effected a 1-for-2.259 reverse stock split of the Company’s outstanding common stock
Reverse stock spilt conversion ratio		0.44267375
Net loss \| $			$ (8,205)	$ (7,676)	$ (7,784)	$ (7,381)	$ (4,199)	$ (2,247)	$ (23,665)	(13,827)
Accumulated deficit \| $			71,906						71,906		$ 48,241
Cash and cash equivalents \| $			$ 299,516						$ 299,516		$ 128,280
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Undesignated preferred stock, authorized			10,000,000						10,000,000
IPO
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial public offering, Shares	12,535,000
Public offering price \| $ / shares	$ 17.00
Proceeds from initial public offering \| $	$ 198,200
Offering costs payable \| $	$ 2,300
Conversion of convertible preferred stock into common stock	21,967,316
Number of shares authorized for issuance	500,000,000
Par value of common stock \| $ / shares	$ 0.0001
Undesignated preferred stock, authorized	10,000,000
Preferred stock, Par Value \| $ / shares	$ 0.0001
Net loss \| $			$ (8,200)			$ (7,400)			$ (23,700)	$ (13,800)
Underwrites Option \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial public offering, Shares	1,635,000

Stock-Based Compensation - Summary of Restricted Common Stock Activity (Details) - Restricted Stock	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance \| shares	1,907,102
Granted \| shares	0
Vested \| shares	(517,252)
Cancelled or forfeited \| shares	(317,796)
Ending balance \| shares	1,072,054
Beginning balance \| $ / shares	$ 1.17
Granted \| $ / shares	0
Vested \| $ / shares	0.85
Cancelled or forfeited \| $ / shares	0.71
Ending balance \| $ / shares	$ 0.63

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Temporary Equity, Shares Authorized		49,624,190
Temporary Equity, Shares Issued		49,624,187
Temporary Equity, Shares Outstanding		49,624,187
Temporary Equity, Liquidation Preference		$ 160,970
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	500,000,000	72,731,000
Common stock issued (in shares)	39,270,140	4,237,290
Common Stock, Shares, Outstanding	39,270,140	4,237,290
Preferred stock, Par Value	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	0
Preferred stock, shares issued	0	0
Preferred shares outstanding	0	0
Series A-1 Redeemable Convertible Preferred Stock
Temporary Equity, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Temporary Equity, Shares Authorized		13,970,000
Temporary Equity, Shares Issued		13,970,000
Temporary Equity, Shares Outstanding		13,970,000
Temporary Equity, Liquidation Preference		$ 13,970
Series A-2 Redeemable Convertible Preferred Stock
Temporary Equity, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Temporary Equity, Shares Authorized		13,750,000
Temporary Equity, Shares Issued		13,750,000
Temporary Equity, Shares Outstanding		13,750,000
Temporary Equity, Liquidation Preference		$ 22,000
Series A-3 Redeemable Convertible Preferred Stock
Temporary Equity, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Temporary Equity, Shares Authorized		7,812,501
Temporary Equity, Shares Issued		7,812,501
Temporary Equity, Shares Outstanding		7,812,501
Temporary Equity, Liquidation Preference		$ 20,000
Series B Redeemable Convertible Preferred Stock
Temporary Equity, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Temporary Equity, Shares Authorized		14,091,689
Temporary Equity, Shares Issued		14,091,686
Temporary Equity, Shares Outstanding		14,091,686
Temporary Equity, Liquidation Preference		$ 105,000

Subsequent Events

9 Months Ended

Sep. 30, 2022

Subsequent Events [Abstract]

Subsequent Events

14. Subsequent Events

Cambridge and San Francisco Leases

On October 21, 2022, the Company entered into two separate lease agreements, one for office space located in Cambridge, Massachusetts (the "Cambridge Lease Agreement"), and one for office space located in San Francisco, California (the "San Francisco Lease Agreement"). The Cambridge Lease Agreement and the San Francisco Lease Agreement are expected to commence in December 2022, and each have an initial term of 63 months. The aggregate estimated rental payments due over the initial term of the Cambridge Lease Agreement is approximately $4.0 million, and the aggregate estimated rental payments due over the initial term of the San Francisco Lease Agreement is approximately $1.8 million.

Stock-Based Compensation - Summary of Stock Options Valuation Assumptions (Details) - Stock Options - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 6 months 10 days
Expected volatility	83.50%	82.40%
Risk-free interest rate	2.69%	0.87%	1.70%	0.87%
Risk-free interest rate		0.92%	2.69%	1.20%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Fair value of common stock	$ 8.60	$ 1.90	$ 8.60	$ 1.90
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)		6 years 6 months 10 days	6 years 6 months 10 days	6 years 6 months 10 days
Expected volatility			83.50%	84.20%
Fair value of common stock	9.22		$ 9.22
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)		6 years 21 days	5 years 8 months 15 days	6 years 21 days
Expected volatility			81.90%	82.40%
Fair value of common stock	$ 8.61		$ 8.61

Novartis License Agreement - Additional Information (Details)			9 Months Ended
	Feb. 28, 2021 USD ($)	Jun. 28, 2019 USD ($) License shares	Sep. 30, 2022 USD ($) License shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 shares	Feb. 24, 2021 shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
License Agreement [Line Items]
Preferred stock, shares issued \| shares			0		0
Novartis License Agreement \| Novartis
License Agreement [Line Items]
Number of licensed compounds \| License		2
Number of licensed Product \| License		1
Upfront cash payment		$ 400,000
Total initial consideration transferred		3,400,000
Changes in fair value of anti dilution right liability			$ 0	$ 700,000
Aggregate milestone payments		231,700,000
Number of development milestone payments \| License			2
Development milestone payments			$ 1,000,000.0
Milestone payments achieved and paid							$ 600,000	$ 400,000
Novartis License Agreement \| Novartis \| Research and Development Expense
License Agreement [Line Items]
Initial fair value of anti-dilution right liability		$ 1,000,000.0
Novartis License Agreement \| Series A-1 Preferred Stock \| Maximum
License Agreement [Line Items]
Preferred stock, shares issued \| shares		6,383,142
Novartis License Agreement \| Series A-1 Preferred Stock \| Novartis
License Agreement [Line Items]
Preferred stock, shares issued \| shares		3,449,808
Fair value of stock		$ 3,000,000.0
Ownership interest		15.00%
Licensing milestone in sales of equity securities	$ 30,000,000.0	$ 30,000,000.0
Novartis License Agreement \| Series A-1 Preferred Stock \| Novartis \| Minimum
License Agreement [Line Items]
Licensing milestone in sales of equity securities		$ 30,000,000.0
Novartis License Agreement \| Series A-1 Preferred Stock \| Novartis \| Maximum
License Agreement [Line Items]
Preferred stock, shares issued \| shares						5,970,000

Income Taxes

9 Months Ended

Sep. 30, 2022

Income Tax Disclosure [Abstract]

Income Taxes

9. Income Taxes

During the three and nine months ended September 30, 2021 and 2022, the Company recorded no income tax provision or benefit.

The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company has considered its history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, as of September 30, 2022, the Company has maintained a full valuation allowance against its remaining net deferred tax assets.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (23,665)	$ (13,827)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,618	275
Change in fair value of preferred stock tranche liability	0	(105)
Change in fair value of anti-dilution liability	0	682
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(3,169)	(345)
Other assets	(1,193)	0
Accounts payable	1,204	740
Accrued expenses and other current liabilities	(1,425)	1,175
Net cash used in operating activities	(25,630)	(11,405)
Cash flows from investing activities:
Net cash used in investing activities	0	0
Cash flows from financing activities:
Proceeds from issuance of preferred stock, net of issuance costs	0	15,922
Proceeds from issuance of common stock in initial public offering, net of issuance costs and underwriting fees	198,178	0
Proceeds from the exercise of stock options	107	0
Payment of offering costs	(1,419)	0
Net cash provided by (used in) financing activities	196,866	15,922
Net increase (decrease) in cash and cash equivalents	171,236	4,517
Cash and cash equivalents at beginning of period	128,280	8,277
Cash and cash equivalents at end of period	$ 299,516	$ 12,794
Supplemental disclosure of cash flows:
Conversion of preferred stock into common stock	170,184	0
Offering costs included in accrued liabilities	$ 875	$ 0
Preferred stock tranche liability established in connection with the issuance of redeemable convertible preferred stock	0	2,979
Issuance of redeemable convertible preferred stock in settlement of preferred stock tranche liability	0	825
Gain on extinguishment of preferred stock tranche liability record to additional paid in capital	0	750
Issuance of redeemable convertible preferred stock in settlement of anti-dilution right liability	$ 0	$ 1,565

Stock-Based Compensation

9 Months Ended

Sep. 30, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

8. Stock-Based Compensation

2019 Stock Incentive Plan

The Company's 2019 Stock Incentive Plan (the “2019 Plan”) provided for the Company to grant incentive stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. The 2019 Plan was administered by the Board or, at the discretion of the Board, by a committee delegated by Board. The exercise prices, vesting and other restrictions were determined at the discretion of the Board, or its committee if so delegated. The Company’s Board valued the Company’s common stock, taking into consideration its most recently available valuation of common stock performed by third party valuation specialists as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant.

The total number of shares of common stock that could have been issued under the 2019 Plan was 5,317,559 shares, of which 283,808 shares remained available for grant on September 19, 2022, the date that the Company's 2022 Equity Incentive Plan (the "2022 Plan") became effective. Upon the effectiveness of the 2022 Plan, the 283,808 remaining shares available under the 2019 Plan were transferred and became available for issuance under the 2022 Plan. Shares of common stock underlying outstanding awards under the 2019 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added to the shares of common stock available for issuance under the 2022 Plan.

2022 Plan

The 2022 Plan was approved by the Board and stockholders in August 2022. The 2022 Plan became effective on September 14, 2022 and replaced the Company's 2019 Plan on that date. The 2022 Plan authorizes the award of incentive stock options ("ISOs"), non-qualified stock options ("NQSOs"), Restricted Stock Awards ("RSAs"), Stock Appreciation Rights ("SARs"), Restricted Stock Units ("RSUs"), performance awards and stock bonus awards. Pursuant to the 2022 Plan, ISOs may be granted only to employees.

The number of shares initially reserved for issuance under the 2022 Plan is 4,710,545 shares of common stock, which includes the 283,808 shares transferred from the 2019 Plan, and shall automatically increase on January 1 of each of 2023 through 2032 by the number of shares equal of the lesser of 5% of the aggregate number of shares of all classes of the common stock, plus the total number of shares of common stock issuable upon conversion of any preferred stock (if any) or exercise of any pre-funded warrants, as issued and outstanding as of the immediately preceding December 31, or a number as may be determined by the Board.

The 2022 Plan is administered by the Board or, at the discretion of the Board, by a committee of the Board. The exercise prices, vesting and other restrictions are determined at the discretion of the Board, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of stock option may not be greater than ten years.

Shares that are expired terminated, surrendered or cancelled under the 2022 Plan without having been fully exercised will be available for future awards.

Stock Options

The assumptions that the Company used to determine the grant-date fair value of stock options awarded to employees, were as follows for the nine months ended September 30, 2021 and 2022:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2022			2021		2022
Expected term (in years)	6.06-6.53				6.53		6.06-6.53		5.71-6.53
Expected volatility		82.4	%		83.5	%	82.4 - 84.2%		81.9-83.5%
Risk-free interest rate	0.87-0.92%				2.69	%	0.87-1.20%		1.70-2.69%
Expected dividend yield		—			—			—		—
Fair value of common stock	$	1.90		$	8.60		$	1.90	$8.61-$9.22

The following table summarizes the Company’s stock option activity since December 31, 2021:


	Number of Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2021		394,254		$	0.85		9.08	$	3,294
Granted		2,348,073			9.02
Exercised		(13,282	)		7.92
Forfeited or cancelled		(186,109	)		8.15
Outstanding as of September 30, 2022		2,542,936		$	7.82		9.59	$	28,343
Options vested and exercisable as of September 30, 2022		246,878		$	4.51		8.95	$	3,667
Options unvested as of September 30, 2022		2,296,058		$	8.19		9.27	$	26,689

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock.

The weighted-average grant-date fair value per share of stock options granted during the nine months ended September 30, 2022 was $6.53. As of September 30, 2022, there was $12.9 million of unrecognized stock-based compensation expense related to unvested stock options, to be recognized over a weighted-average period of 4.21 years.

The total fair value of options vested during the nine months ended September 30, 2022 was $0.6 million.

Included within the total stock options outstanding are 113,970 stock options to purchase common stock which have performance-based vesting criteria and were granted to certain employees, officers and consultants of the Company on various dates during the years ended December 31, 2020 and 2021 (collectively, the “Performance Stock Options”). Vesting of 37,133 of the Performance Stock Options was contingent on the closing of the Series A-2 Second Tranche, which occurred on February 24, 2021, and vesting of the remaining 97,938 Performance Stock Options was contingent on the closing of the Series A-3 Second Tranche, which occurred on November 15, 2021. The vesting commencement date of the Performance Stock Options was the date in which the performance condition is met, and vesting occurs based on the accelerated attribution method over four years from the vesting commencement date. The Company began to recognize expense associated with the Performance Stock Options on the date in which each respective performance criteria was met and recognized total stock-based compensation expense associated with the Performance Stock Options of less than $0.1 million for the nine months ended September 30, 2022. No expense associated with the Performance Stock Options was recognized prior to the year ended December 31, 2021.

Restricted Common Stock Awards

The Company has granted restricted common stock awards with service and performance and service based vesting conditions to employees of the Company. Unvested shares of restricted common stock may not be sold or transferred by the holder, except for transfers for estate planning purposes in which the transferee agrees to remain bound by all restrictions set forth in the original common stock purchase agreement. These restrictions lapse over the vesting term of each award, which is typically four years. The purchase price of each share of restricted common stock was $0.0001 per share.

On August 9, 2021, the Company’s chief executive office (“CEO”) purchased 1,218,836 shares of common stock at a purchase price of $1.44 per share, under the terms of a restricted common stock award granted under the 2019 Plan. These shares were purchased in exchange for a promissory note (the “Promissory Note”) of $1.8 million. The shares granted include both service and performance-based vesting criteria and accrued at an interest rate of 0.76% per annum, compounded annually and were accounted for as restricted stock.

On August 22, 2022, the Company forgave the entire promissory note, including principal and accrued and unpaid interest. As a result this is considered a modification to the original awards, and the Company recognized the grant date fair value plus any incremental fair value due to the modification. The incremental cost was measured as the difference between the fair value of the award at modification date and the fair value of the original award immediately prior to modification. As a result of accounting for the modification, the Company recorded an incremental stock based compensation charge of $1.0 million, which will be recognized over the remaining requisite service period of award from the date of the modification.

The CEO was paid a one-time special bonus of $1.9 million to offset the CEO’s tax liability as a result of the forgiveness of the promissory note (the “Tax Payment”), which is subject to a three-year vesting schedule with six-month cliffs. The Company is allowed to claw-back the unvested portion of the Tax Payment in the event that the CEO’s employment is terminated before the end of the three-year vesting period, provided that the CEO’s employment is terminated by the Company other than for cause, or if the CEO resigns for a good reason (a) within 12 months following a change of control, or (b) within 3 months preceding a change in control but as to only if the separation occurs after a potential change in control. In the event the CEO’s employment is terminated, the unvested portion of the Tax Payment will accelerate and will not be subject to the claw back provision. The clawback provision will be accounted for if and when the CEO leaves under the relevant circumstances and the payment amount will be capitalized and recognized over the related service period as G&A employee salary expense.

A summary of the activity of the restricted common stock since December 31, 2021:


	Number of Shares			Weighted-Average Grant Date Fair Value Per Share
Unvested at December 31, 2021		1,907,102		$	1.17
Granted		—			—
Vested		(517,252	)		0.85
Cancelled or forfeited		(317,796	)		0.71
Unvested at September 30, 2022		1,072,054		$	0.63

The weighted-average grant-date fair value per share of restricted common stock awards granted during the nine months ended September 30, 2022 was zero as no shares were granted in the period. The aggregate fair value of restricted stock awards that vested during the nine months ended September 30, 2022 was $0.1 million. Stock-based compensation expense recognized for the restricted stock granted was $0.9 million for the nine months ended September 30, 2022. As of September 30, 2022, there was unrecognized expense of $2.2 million related to the restricted stock, which is expected to be recognized over a weighted-average period of 2.79 years.

Stock-Based Compensation Expense

Stock-based compensation expense included in the Company’s condensed consolidated statements of operations was as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2022		2021		2022
Research and development		55		343		142		723
General and administrative		82		663		133		1,892
Total stock-based compensation expense		137		1,006		275		2,615

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Options Valuation Assumptions

The assumptions that the Company used to determine the grant-date fair value of stock options awarded to employees, were as follows for the nine months ended September 30, 2021 and 2022:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2022			2021		2022
Expected term (in years)	6.06-6.53				6.53		6.06-6.53		5.71-6.53
Expected volatility		82.4	%		83.5	%	82.4 - 84.2%		81.9-83.5%
Risk-free interest rate	0.87-0.92%				2.69	%	0.87-1.20%		1.70-2.69%
Expected dividend yield		—			—			—		—
Fair value of common stock	$	1.90		$	8.60		$	1.90	$8.61-$9.22

Summary of Stock Option Activity

The following table summarizes the Company’s stock option activity since December 31, 2021:


	Number of Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2021		394,254		$	0.85		9.08	$	3,294
Granted		2,348,073			9.02
Exercised		(13,282	)		7.92
Forfeited or cancelled		(186,109	)		8.15
Outstanding as of September 30, 2022		2,542,936		$	7.82		9.59	$	28,343
Options vested and exercisable as of September 30, 2022		246,878		$	4.51		8.95	$	3,667
Options unvested as of September 30, 2022		2,296,058		$	8.19		9.27	$	26,689

Summary of Restricted Common Stock Activity

A summary of the activity of the restricted common stock since December 31, 2021:


	Number of Shares			Weighted-Average Grant Date Fair Value Per Share
Unvested at December 31, 2021		1,907,102		$	1.17
Granted		—			—
Vested		(517,252	)		0.85
Cancelled or forfeited		(317,796	)		0.71
Unvested at September 30, 2022		1,072,054		$	0.63

Summary of Stock-Based Compensation Expense

Stock-based compensation expense included in the Company’s condensed consolidated statements of operations was as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2022		2021		2022
Research and development		55		343		142		723
General and administrative		82		663		133		1,892
Total stock-based compensation expense		137		1,006		275		2,615

Fair Value Measurements - Additional Information (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Fair Value Disclosures [Line Items]
Transfers or reclassifications between fair value measurement levels of assets	$ 0	$ 0
Transfers or reclassifications between fair value measurement levels of liabilities	0	0
Cash and Cash Equivalents
Fair Value Disclosures [Line Items]
Fair value measurement of financial liabilities	$ 0	$ 0

Stockholder's Equity (Deficit) - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended		45 Months Ended
	Sep. 19, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Common Stock, Shares Authorized		500,000,000		500,000,000	72,731,000
Common Stock, Par or Stated Value Per Share		$ 0.0001		$ 0.0001	$ 0.0001
Common stock voting rights				one vote for each share
Common stock, cash dividends declared				$ 0
Common Stock Shares Issued		39,270,140		39,270,140	4,237,290
Offering costs		$ 1,419	$ 0
Conversion of convertible preferred stock into common stock					49,624,187
Common Stock Shares Outstanding		39,270,140		39,270,140	4,237,290
Undesignated preferred stock, authorized		10,000,000		10,000,000	0
Preferred stock, Par Value		$ 0.0001		$ 0.0001	$ 0.0001
Undesignated preferred shares issued		0		0	0
Preferred shares outstanding		0		0	0
Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Undesignated preferred stock, authorized		10,000,000		10,000,000
IPO
Subsidiary, Sale of Stock [Line Items]
Common Stock, Shares Authorized	500,000,000
Initial public offering, Shares	12,535,000
Common Stock, Par or Stated Value Per Share	$ 0.0001
Public offering price	$ 17.00
Proceeds from issuing shares	$ 198,200
Offering costs	$ 2,300
Conversion of convertible preferred stock into common stock	21,967,316
Undesignated preferred stock, authorized	10,000,000
Preferred stock, Par Value	$ 0.0001
Over allotment \| Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Initial public offering, Shares	1,635,000

Net Loss Per Share - Schedule of Computation of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-dilutive Effect (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti diluted effect of diluted net loss per share	3,614,989	2,217,334	3,614,989	2,217,334
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti diluted effect of diluted net loss per share	0	29,673,125	0	29,673,125
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti diluted effect of diluted net loss per share	2,542,936	394,254	2,542,936	394,254
Unvested Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti diluted effect of diluted net loss per share	1,072,054	1,823,080	1,072,054	1,823,080

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,006	$ 137	$ 2,615	$ 275
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	343	55	723	142
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 663	$ 82	$ 1,892	$ 133

Redeemable Convertible Preferred Stock (Tables)

9 Months Ended

Sep. 30, 2022

Temporary Equity Disclosure [Abstract]

Summary of Redeemable Convertible Preferred Stock

As of December 31, 2021, the redeemable convertible preferred stock consisted of the following (in thousands, except share amounts):


	Preferred Stock Authorized		Preferred Stock Issued and Outstanding		Carrying Value		Liquidation Value		Common Stock Issuable Upon Conversion
Series A-1 Preferred Stock		13,970,000		13,970,000	$	12,574	$	13,970		13,970,000
Series A-2 Preferred Stock		13,750,000		13,750,000		19,476		22,000		13,750,000
Series A-3 Preferred Stock		7,812,501		7,812,501		33,288		20,000		7,812,501
Series B Preferred Stock		14,091,689		14,091,686		104,846		105,000		14,091,686
Total		49,624,190		49,624,187	$	170,184	$	160,970		49,624,187

Immediately prior to the closing of the IPO on September 19, 2022, all outstanding shares of our redeemable convertible preferred stock were converted into 21,967,316 shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital. Accordingly, there were no shares of redeemable convertible preferred stock outstanding as of September 30, 2022.

Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 100,498	$ 22,505
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	100,498	22,505
Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	0	0
Significant Other Observable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	0	0
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	100,498	22,505
Money Market Funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	100,498	22,505
Money Market Funds \| Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	0	0
Money Market Funds \| Significant Other Observable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 0	$ 0

Employee Benefit Plans

9 Months Ended

Sep. 30, 2022

Compensation And Retirement Disclosure [Abstract]

Employee Benefit Plans

13. Employee Benefit Plans

Effective January 1, 2019, the Company adopted a 401(k) Plan for its employees, which is designed to be qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. Since inception of the plan and through the nine months ended September 30, 2022 the Company has not made any contributions to the 401(k) Plan.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI https://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Novartis License Agreement

9 Months Ended

Sep. 30, 2022

License Agreement [Abstract]

Novartis License Agreement

5. Novartis License Agreement

On June 28, 2019, the Company entered into a License Agreement (the “Novartis License Agreement”) with Novartis Pharma AG, formerly known as Novartis International Pharmaceutical Ltd, (“Novartis”). Pursuant to the Novartis License Agreement, the Company has been granted an exclusive, worldwide, royalty-bearing, sublicensable license under specified patent rights and know-how related to two licensed compounds, to develop, make, use and sell certain products incorporating or comprising a licensed compound, including THB001, to certain intellectual property rights owned or controlled by Novartis (the “Licensed IP”), to research, develop, make, use, sell, and commercialize products containing the Licensed IP.

Under the Novartis License Agreement, the Company is solely responsible for all research, development, regulatory and commercialization activities related to the Licensed IP. The Company is required to use commercially reasonable efforts to develop and seek regulatory approval for, and commercialize, at least one licensed product in each of the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.

In exchange for these rights, the Company made an upfront cash payment of $0.4 million and issued 3,449,808 shares of Series A-1 Preferred Stock with a fair value of $3.0 million to Novartis. Upon entering into the Novartis License Agreement in 2019, the total initial consideration of $3.4 million transferred to Novartis was charged to expenses as research and development expense. The Company determined that the Novartis License Agreement represented an asset acquisition as it did not meet the definition of a business. The Company recorded the initial consideration transferred to Novartis as research and development expense in the statement of operations because the acquired Licensed IP represented in-process research and development with no alternative future use.

In addition, under the Novartis License Agreement, an anti-dilution right was issued to Novartis, in which Novartis is entitled to receive shares of Series A-1 Preferred Stock, guaranteeing them a 15% ownership interest of the fully diluted capitalization of the Company. The Company was obligated to issue additional shares of Series A-1 Preferred Stock until the Company had (1) raised aggregate cumulative proceeds of $30.0 million from sales of equity securities since its inception; or (2) issued and sold any securities that generate proceeds in excess of $30.0 million. Additionally, the Company was not obligated to issue more than 6,383,142 shares of the Series A-1 Preferred Stock to Novartis under the anti-dilution right. The Company assessed the Novartis anti-dilution right and determined that the right (i) meets the definition of a freestanding financial instrument that is not indexed to the Company’s own stock and (ii) meets the definition of a derivative and does not qualify for equity classification. The initial fair value of the anti-dilution right liability of $1.0 million was recorded as research and development expense in July 2019, as part of the initial consideration in the license agreement. The Company remeasured the liability associated with the anti-dilution right at each reporting date and at each issuance of Series A-1 Preferred Stock under the anti-dilution right. Changes in the fair value were recorded as other income and expense in the statement of operations until the anti-dilution right was satisfied in February 2021 upon the Company raising aggregate cumulative proceeds of $30.0 million in sales of equity securities. As part of the anti-dilution right, the Company issued a total of 5,970,000 shares of Series A-1 Preferred Stock to Novartis. During the nine months ended September 30, 2021, the Company recorded an expense associated with changes in fair value of the anti-dilution right liability of $0.7 million. No expense was recognized during the nine months ended September 30, 2022 as the anti-dilution liability was satisfied in February 2021.

Under the Novartis License Agreement, the Company is obligated to make aggregate milestone payments of up to $231.7 million related to the achievement of specified development, commercialization, and sales milestones. The Company records the milestone payments as research and development expenses when the milestones occur and consideration is paid or becomes payable. As of September 30, 2022, the Company has made two development milestone payments under the Novartis Agreement totaling $1.0 million, of which $0.4 million was achieved and paid in 2019, and $0.6 million was achieved and paid in 2020, which have been recorded as research and development expense. No other milestones have occurred or have been paid under the Novartis License Agreement.

As part of the Novartis License Agreement, the Company also agreed to pay tiered royalties based on future net sales of all products licensed under the agreement, of which the royalty percentage ranged within the single digits.

Redeemable Convertible Preferred Stock - Additional Information (Details) - shares	Sep. 30, 2022	Sep. 19, 2022	Dec. 31, 2021
Temporary Equity [Line Items]
Conversion of convertible preferred stock into common stock			49,624,187
Preferred Stock Outstanding			49,624,187
IPO
Temporary Equity [Line Items]
Conversion of convertible preferred stock into common stock		21,967,316
Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Outstanding	0
Common Stock \| IPO
Temporary Equity [Line Items]
Conversion of convertible preferred stock into common stock		21,967,316

Accrued Expenses and Other Current Liabilities (Tables)

9 Months Ended

Sep. 30, 2022

Payables And Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	December 31, 2021		September 30, 2022
Accrued research and development expenses	$	2,685	$	893
Professional fees		450		1,039
Employee compensation and related benefits		752		1,068
Other		2		3
Total accrued expenses and other current liabilities	$	3,889	$	3,003

Stockholder's Equity (Deficit) (Tables)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Schedule of Common Stock Reserved for Issuance

The following shares of common stock were reserved for issuance as follows:


	December 31, 2021		September 30, 2022
Conversion of outstanding shares of preferred stock		21,967,316		—
Options to purchase common stock		394,254		2,542,936
Unvested restricted common stock		1,907,102		1,072,054
Remaining shares reserved for future issuance		2,065,764		4,710,545
Total		26,334,436		8,325,534

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Schedule of Financial Assets Measured at Fair Value

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis (in thousands):


			December 31, 2021
Description	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Observable Inputs (Level 3)
Money market funds	$	22,505	$	22,505	$	—	$	—
Total financial assets	$	22,505	$	22,505	$	—	$	—


			September 30, 2022
Description	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Observable Inputs (Level 3)
Money market funds	$	100,498	$	100,498	$	—	$	—
Total financial assets	$	100,498	$	100,498	$	—	$	—

Related Party Transactions

9 Months Ended

Sep. 30, 2022

Related Party Transactions

12. Related Party Transactions

Entities Affiliated with Atlas Venture Fund XI, L.P.

Entities affiliated with Atlas Venture Fund XI, L.P. are a significant beneficial owner of the Company, holding more than 5% of the total outstanding stock of the Company, as of December 31, 2021 and September 30, 2022. The Company leased various office space from Atlas for use in its daily operations.

During each of the three months ended September 30, 2021 and 2022, the Company made payments of less than $0.1 million and $0.1 million and during the nine months ended September 30, 2021 and 2022, the Company made payments of $0.1 million and $0.1 million, respectively associated with the lease agreements with Atlas, which was recorded within the general and administrative expense.

Novartis

Novartis is a significant beneficial owner of the Company, holding more than 5% of the total outstanding stock of the Company, as of December 31, 2021 and September 30, 2022. The Company has an in-license agreement with Novartis, which required the Company to make an upfront payment and issue shares of Series A-1 Preferred Stock to Novartis, and further includes future milestone payments upon the occurrence of certain events and royalty payments upon future sales. Refer to Note 5.

CEO Promissory Note

On August 9, 2021, the Company entered into the Promissory Note with the CEO for an amount of $1.8 million, which was used to allow the CEO to purchase 1,218,836 shares of common stock granted in the form of a restricted stock award under the 2019 Plan. The Promissory Note had a stated interest rate of 0.76%, which was compounded annually. The entire Promissory Note, including principal and accrued and unpaid interest, was forgiven on August 22, 2022. The Company has paid the CEO a one-time special bonus of $1.9 million, which was paid to offset the CEO's tax liability as a result of the forgiveness of the Promissory Note. This is subject to a three-year vesting schedule with six-month cliffs, as well as continued employment with the company on the relevant vesting dates. Refer to Note 8.

Consulting Agreements

In June 2019, the Company entered into a consulting agreement with Mark Iwicki, the chairman of the Board, for consulting services. Pursuant to this agreement, Mr. Iwicki was granted a restricted stock award for 47,100 shares of the Company’s common stock, with 1/48th of the shares subject to the award vesting in equal monthly installments. The Company recognized stock-based compensation of $6.1 thousand and $6.1 thousand, respectively, for the nine months ended September 30, 2021 and 2022, which was recorded within general and administrative expense.

In July 2019, the Company entered into a consulting agreement with H. Martin Seidel, in connection with his appointment to the Board and the Company’s scientific advisory board, for consulting services. The Company will make payments of $25.0 thousand per year for such consulting services, payable quarterly in arrears. In addition, Dr. Seidel was granted a restricted stock award of 75,360 shares of the Company’s common stock, with 25% of the shares subject to the award vesting on July 25, 2020 and the remaining shares vesting in equal quarterly installments thereafter until July 25, 2023. The Company recognized stock-based compensation of $9.8 thousand and $9.8 thousand, respectively, for the nine months ended September 30, 2021 and 2022, which was recorded within general and administrative expense.

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 299,516	$ 128,280
Prepaid expenses and other current assets	4,053	884
Total current assets	303,569	129,164
Other assets	1,193	0
Total assets	304,762	129,164
Current liabilities:
Accounts payable	3,337	1,797
Accrued Expense And Other Current Liabilities	3,003	3,889
Total current liabilities	6,340	5,686
Preferred stock tranche liability	0	0
Anti-dilution liability	0	0
Total liabilities	6,340	5,686
Commitments and contingencies (Note 11)
Redeemable convertible preferred stock		170,184
Stockholders’ deficit:
Common stock, $0.0001 par value, 72,731,000 and 500,000,000 shares authorized at December 31, 2021 and September 30, 2022; 4,237,290 and 39,270,140 shares issued and outstanding at December 31, 2021 and September 30, 2022, respectively	4	1
Preferred stock, $0.0001 par value, - and 10,000,000 shares authorized at December 31, 2021 and September 30, 2022; - and - shares issued and outstanding at December 31, 2021 and September 30 , 2022, respectively
Additional paid-in capital	370,324	1,534
Accumulated deficit	(71,906)	(48,241)
Total stockholders' (deficit) equity	298,422	(46,706)
Total liabilities, redeemable convertible preferred stock and stockholders’ deficit	304,762	129,164
Series A-1 Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred stock	0	12,574
Series A-2 Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred stock	0	19,476
Series A-3 Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred stock	0	33,288
Series B Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred stock	$ 0	$ 104,846

Stockholder's Equity (Deficit)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Stockholder's Equity (Deficit)

7. Stockholder's Equity (Deficit)

Common stock

As of December 31, 2021 and September 30, 2022, the Company’s Amended and Restated Certificate of Incorporation authorized the Company to issue 72,731,000 and 500,000,000 shares of common stock, with a par value of $0.0001, respectively. The voting, dividend and liquidation rights of the holders of the Company’s common stock were subject to and qualified by the rights, preferences and privileges of the holders of the redeemable convertible preferred stock set forth in the Company's audited annual consolidated financial statements and related notes included in the registration statement on Form S-1, as amended (Registration No. 333-267022) (“Registration Statement”).

The holders of the common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. There are not cumulative voting rights for the election of directors in the restated certificate of incorporation, which means that holders of a majority of the shares of the common stock will be able to elect all of the directors. Common stockholders are entitled to receive dividends, as may be declared by the board of directors (the "Board"), if any, subject to the preferential dividend rights of redeemable convertible preferred stock. Through September 30, 2022, no cash dividends had been declared or paid.

On September 19, 2022, the Company completed its IPO, at which time the Company issued 12,535,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,635,000 additional shares of common stock, at a public offering price of $17.00 per share. The Company received $198.2 million, net of underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2.3 million. Upon the closing of the IPO, all outstanding shares of redeemable convertible preferred stock converted into 21,967,316 shares of common stock (see Note 6). As of December 31, 2021 and September 30, 2022, there were 4,237,290 and 39,270,140 shares of common stock issued and outstanding, respectively.

The following shares of common stock were reserved for issuance as follows:


	December 31, 2021		September 30, 2022
Conversion of outstanding shares of preferred stock		21,967,316		—
Options to purchase common stock		394,254		2,542,936
Unvested restricted common stock		1,907,102		1,072,054
Remaining shares reserved for future issuance		2,065,764		4,710,545
Total		26,334,436		8,325,534

Undesignated preferred stock

As of September 30, 2022, the Company’s Amended and Restated Certificate of Incorporation authorized the Company to issue up to 10,000,000 shares of undesignated preferred stock, par value $0.0001 per share. There were no undesignated preferred shares issued or outstanding as of September 30, 2022.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2022
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), for interim financial reporting and as required by Regulation S-X, Rule 10-01. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated annual financial statements for the years ended December 31, 2020 and 2021 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2022, the condensed consolidated statement of stockholders' equity (deficit) as of September 30, 2022 and condensed consolidated statements of cash flows for the nine months ended September 30, 2021 and 2022. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2021 and 2022 are unaudited. The results for the nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s condensed consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. In December 2019, the FASB issued ASU No. 2019-12 (“ASU-2019-12”), Simplifying the Accounting for Income Tax, which contains several provisions that reduce financial statement complexity including removing the exception to the incremental approach for intra-period tax expense allocation when a company has a loss from continuing operations and income from other items not included in continuing operations. The Company adopted this accounting standard as of January 1, 2022 with no material impact on its condensed consolidated financial statements.

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share amounts):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2022		2021		2022
Numerator:
Net loss	$	7,381	$	8,205	$	13,827	$	23,665
Net loss attributable to common stockholders, basic and diluted	$	7,381	$	8,205	$	13,827	$	23,665
Denominator:
Weighted-average number of common shares used in net loss per share, basic and diluted		8,159,044		11,827,663		3,994,784		10,451,300
Net loss per share of common stock, basic and diluted	$	0.90	$	0.69	$	3.46	$	2.26

Schedule of Computation of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-dilutive Effect

The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders during the three and nine months ended September 30, 2021 and 2022 because including them would have had an anti-dilutive effect:


	Three and Nine Months Ended September 30,
	2021		2022
Redeemable convertible preferred stock		29,673,125		—
Options to purchase common stock		394,254		2,542,936
Unvested restricted stock		1,823,080		1,072,054
Total		2,217,334		3,614,989

Stockholder's Equity (Deficit) - Schedule of Common Stock Reserved for Issuance (Details) - shares	Sep. 30, 2022	Dec. 31, 2021
Conversion of outstanding shares of preferred stock	0	21,967,316
Options to purchase common stock	2,542,936	394,254
Unvested restricted common stock	1,072,054	1,907,102
Remaining shares reserved for future issuance	4,710,545	2,065,764
Total	8,325,534	26,334,436

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2022	Nov. 01, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Period End Date	Sep. 30, 2022
Current Fiscal Year End Date	--12-31
Entity Registrant Name	THIRD HARMONIC BIO, INC.
Entity Central Index Key	0001923840
Entity File Number	001-41498
Entity Tax Identification Number	83-4553503
Entity Interactive Data Current	Yes
Entity Current Reporting Status	No
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Incorporation, State or Country Code	DE
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Address, Address Line One	300 Technology Square, 8th Floor
Entity Address, State or Province	MA
Entity Address City Or Town	Cambridge
Entity Address, Postal Zip Code	02139
City Area Code	617
Local Phone Number	915-6680
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Common Stock, Shares Outstanding		40,544,756
Trading Symbol	THRD
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 4,757	$ 4,917	$ 15,150	$ 11,463
General and administrative	3,831	780	9,008	1,790
Total operating expenses	8,588	5,697	24,158	13,253
Loss from operations	8,588	5,697	24,158	13,253
Other (income) expense, net:
Change in fair value of anti-dilution right liability	0	0	0	682
Change in fair value of preferred stock tranche liability	0	1,685	0	(105)
Other (income)	(383)	(1)	(493)	(3)
Total other (income) expense, net	(383)	1,684	(493)	574
Net loss	$ 8,205	$ 7,381	$ 23,665	$ 13,827
Net loss per share of common stock, basic	$ 0.69	$ 0.90	$ 2.26	$ 3.46
Net loss per share of common stock, diluted	$ 0.69	$ 0.90	$ 2.26	$ 3.46
Weighted-average common stock outstanding, basic	11,827,663	8,159,044	10,451,300	3,994,784
Weighted-average common stock outstanding, diluted	11,827,663	8,159,044	10,451,300	3,994,784

Stock-Based Compensation - Additional Information (Details) - USD ($)					3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 22, 2022	Nov. 15, 2021	Aug. 09, 2021	Feb. 24, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Sep. 19, 2022	Sep. 14, 2022	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance					8,325,534		8,325,534		26,334,436
Stock-based compensation expense					$ 1,006,000	$ 137,000	$ 2,615,000	$ 275,000
CEO Promissory Note
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period							3 years
Special bonus paid	$ 1,900,000
Award vesting description							subject to a three-year vesting schedule with six-month cliffs
Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Service period							3 months
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant date fair value per share of stock options							$ 6.53
Unrecognized stock-based compensation expense related to unvested stock options					$ 12,900,000		$ 12,900,000
Unrecognized stock based compensation expense period of recognition							4 years 2 months 15 days
Fair value of options vested							$ 600,000
Outstanding stock options to purchase common stock					2,542,936		2,542,936		394,254
Share price					$ 8.60	$ 1.90	$ 8.60	$ 1.90
Performance Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting over period							4 years
Stock-based compensation expense									$ 0
Performance Stock Options \| Performance Based Vesting
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding stock options to purchase common stock									113,970			113,970
Performance Stock Options \| Series A-2 Second Tranche
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting of performance stock				37,133
Performance Stock Options \| Series A-3 Second Tranche
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting of remaining performance stock		97,938
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period							4 years
Unrecognized stock based compensation expense period of recognition							2 years 9 months 14 days
Stock-based compensation expense							$ 900,000
Share price					$ 0.0001		$ 0.0001
Remaining unrecognized expense	1,000,000.0
Weighted average grant date fair value							$ 0
Granted in period							0
Aggregate fair value of restricted stock awards vested							$ 100,000
Unrecognized expense					$ 2,200,000		$ 2,200,000
Restricted Stock \| Promissory Note
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exchangeable value of shares purchased			$ 1,800,000
Restricted Stock \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share price			$ 1.44
Number of shares purchased			1,218,836
Special bonus paid	$ 1,900,000
Contingency period							12 months
Restricted Stock \| Chief Executive Officer [Member] \| Promissory Note
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Accrued Interest Rate			0.76%
2019 Stock Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common stock issuable under plan										5,317,559
Conversion of outstanding shares of preferred stock										283,808	283,808
Number of shares transferred					283,808		283,808
2022 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance					4,710,545		4,710,545
Maximum \| Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share price					$ 9.22		$ 9.22
Maximum \| Performance Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense							$ 100,000
Maximum \| 2022 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of annual increase in number of shares to classes of common stock under plan							5.00%
Exercise price per share of stock options as percentage of fair market value of common stock							100.00%
Stock option expiration period							10 years
Minimum \| Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share price					$ 8.61		$ 8.61

Fair Value Measurements

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

3. Fair Value Measurements

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis (in thousands):


			December 31, 2021
Description	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Observable Inputs (Level 3)
Money market funds	$	22,505	$	22,505	$	—	$	—
Total financial assets	$	22,505	$	22,505	$	—	$	—


			September 30, 2022
Description	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Observable Inputs (Level 3)
Money market funds	$	100,498	$	100,498	$	—	$	—
Total financial assets	$	100,498	$	100,498	$	—	$	—

As of December 31, 2021 and September 30, 2022, the Company had no financial liabilities that required fair value measurement. As of December 31, 2021 and September 30, 2022, the Company’s cash equivalents consisted of money market funds, classified as Level 1 financial assets, as these assets are valued using quoted market prices in active markets without any valuation adjustment.

During the year ended December 31, 2021 and nine months ended September 30, 2022 there were no transfers or reclassifications between fair value measurement levels of assets or liabilities. The carrying values of prepaid and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated annual financial statements for the years ended December 31, 2020 and 2021, included in our final prospectus for the IPO. Since the date of those annual financial statements, there have been no changes to the Company’s significant accounting policies, except as noted below.

Unaudited Interim Financial Information

The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), for interim financial reporting and as required by Regulation S-X, Rule 10-01. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated annual financial statements for the years ended December 31, 2020 and 2021 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2022, the condensed consolidated statement of stockholders' equity (deficit) as of September 30, 2022 and condensed consolidated statements of cash flows for the nine months ended September 30, 2021 and 2022. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2021 and 2022 are unaudited. The results for the nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s condensed consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.

In December 2019, the FASB issued ASU No. 2019-12 (“ASU-2019-12”), Simplifying the Accounting for Income Tax, which contains several provisions that reduce financial statement complexity including removing the exception to the incremental approach for intra-period tax expense allocation when a company has a loss from continuing operations and income from other items not included in continuing operations. The Company adopted this accounting standard as of January 1, 2022 with no material impact on its condensed consolidated financial statements.

Related Party Transactions - Additional Information (Details) - USD ($)				1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 22, 2022	Aug. 09, 2021	Jul. 25, 2020	Jul. 31, 2019	Jun. 30, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Common stock issued (in shares)						39,270,140		39,270,140		4,237,290
Stock-based compensation expense						$ 1,006,000	$ 137,000	$ 2,615,000	$ 275,000
General and Administrative
Related Party Transaction [Line Items]
Stock-based compensation expense						663,000	82,000	1,892,000	133,000
Atlas Venture Fund XI, L.P \| General and Administrative
Related Party Transaction [Line Items]
Related party transaction payment						$ 100,000		$ 100,000	100,000
Atlas Venture Fund XI, L.P \| Minimum
Related Party Transaction [Line Items]
Outstanding stock percentage								5.00%		5.00%
Atlas Venture Fund XI, L.P \| Maximum \| General and Administrative
Related Party Transaction [Line Items]
Related party transaction payment							$ 100,000
Novartis \| Minimum
Related Party Transaction [Line Items]
Outstanding stock percentage								5.00%		5.00%
CEO Promissory Note
Related Party Transaction [Line Items]
Promissory note agreement amount		$ 1,800,000
Common stock issued (in shares)		1,218,836
Interest rate of promissory note		0.76%
Special bonus paid	$ 1,900,000
Vesting period								3 years
Award vesting description								subject to a three-year vesting schedule with six-month cliffs
Consulting Agreement \| Mark Iwicki
Related Party Transaction [Line Items]
Restricted stock, granted					47,100
Award vesting description								with 1/48th of the shares subject to the award vesting in equal monthly installments.
Consulting Agreement \| H Martin Seidel
Related Party Transaction [Line Items]
Related party transaction payment				$ 25,000.0
Restricted stock, granted				75,360
Vesting rights, percentage			25.00%
Award vesting date			Jul. 25, 2020
Consulting Agreement \| General and Administrative \| Mark Iwicki
Related Party Transaction [Line Items]
Stock-based compensation expense								$ 6,100	6,100
Consulting Agreement \| General and Administrative \| H Martin Seidel
Related Party Transaction [Line Items]
Stock-based compensation expense								$ 9,800	$ 9,800

Commitments and Contingencies

9 Months Ended

Sep. 30, 2022

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

11. Commitments and Contingencies

Legal Proceedings

From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of December 31, 2021 and September 30, 2022, there were no litigation matters which would have a material impact on the Company’s financial results.

Leases

The Company’s operating leases comprised of month-to-month office space leases entered into with Atlas Venture Life Science Advisors ("Atlas") and other third parties for various office suites. As the Company has elected to not recognize leases with a lease term of 12 months or less on the balance sheet, no operating lease right of use asset and liability has been recognized as of December 31, 2021 and September 30, 2022. The Company incurred less than $0.1 million and $0.1 million of expenses during the three months ended September 30, 2021 and 2022 and $0.1 million and $0.1 million of expenses during the nine months ended September 30, 2021 and 2022, respectively.

Stock-Based Compensation - Summary of Stock Option Activity (Details) - Stock Options $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance \| shares	394,254
Shares, Granted \| shares	2,348,073
Exercised \| shares	(13,282)
Forfeited or cancelled \| shares	(186,109)
Ending balance \| shares	2,542,936	394,254
Options vested and exercisable as of September 30, 2022 \| shares	246,878
Options unvested as of September 30, 2022 \| shares	2,296,058
Beginning balance \| $ / shares	$ 0.85
Granted \| $ / shares	9.02
Exercised \| $ / shares	7.92
Forfeited or cancelled \| $ / shares	8.15
Ending balance \| $ / shares	7.82	$ 0.85
Options vested and exercisable as of September 30, 2022 \| $ / shares	4.51
Options unvested as of September 30, 2022 \| $ / shares	$ 8.19
Weighted-Average Remaining Contractual Term (in years)	9 years 7 months 2 days	9 years 29 days
Options vested and exercisable as of September 30, 2022	8 years 11 months 12 days
Aggregate Intrinsic Value \| $	$ 28,343	$ 3,294
Options vested and exercisable as of September 30, 2022 \| $	3,667
Options unvested as of September 30, 2022 \| $	$ 26,689
Options unvested as of September 30, 2022	9 years 3 months 7 days

Redeemable Convertible Preferred Stock

9 Months Ended

Sep. 30, 2022

Temporary Equity Disclosure [Abstract]

Redeemable Convertible Preferred Stock

6. Redeemable Convertible Preferred Stock

As of December 31, 2021, the redeemable convertible preferred stock consisted of the following (in thousands, except share amounts):


	Preferred Stock Authorized		Preferred Stock Issued and Outstanding		Carrying Value		Liquidation Value		Common Stock Issuable Upon Conversion
Series A-1 Preferred Stock		13,970,000		13,970,000	$	12,574	$	13,970		13,970,000
Series A-2 Preferred Stock		13,750,000		13,750,000		19,476		22,000		13,750,000
Series A-3 Preferred Stock		7,812,501		7,812,501		33,288		20,000		7,812,501
Series B Preferred Stock		14,091,689		14,091,686		104,846		105,000		14,091,686
Total		49,624,190		49,624,187	$	170,184	$	160,970		49,624,187

Nature of the Business

9 Months Ended

Sep. 30, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Nature of the Business

1. Nature of the Business

Third Harmonic Bio, Inc., (the “Company”) is a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and inflammation.

The Company was incorporated in 2019 as a Delaware corporation, and its principal office is located in Cambridge, Massachusetts. In December 2021, the Company formed THB MS, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, which is classified as a Security Corporation in Massachusetts.

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, completion and success of clinical testing, development by competitors of new technological innovations, compliance with governmental regulations, dependence on key personnel and protection of proprietary technology and the ability to secure additional capital to fund operations. THB001 will require extensive clinical testing prior to regulatory approval and commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

Initial public offering

On September 19, 2022, the Company closed its initial public offering (“IPO”), and issued 12,535,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,635,000 additional shares of common stock, at a public offering price of $17.00 per share. The Company received $198.2 million, net of underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2.3 million. Immediately prior to the closing of the IPO, all outstanding shares of redeemable convertible preferred stock converted into 21,967,316 shares of common stock (see Note 6). In connection with the closing of its IPO, on September 19, 2022, the Company amended its certificate of incorporation to authorize the issuance of up to 500,000,000 shares of $0.0001 par value common stock and 10,000,000 shares of $0.0001 par value preferred stock.

Reverse stock split

On September 7, 2022, the Company effected a 1-for-2.259 reverse stock split of the Company’s outstanding common stock. All common stock, stock options and per share information presented in the unaudited condensed consolidated financial statements have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented. There was no change in the par value of the Company’s common stock. The ratio by which shares of preferred stock are convertible into shares of common stock was adjusted to reflect the effects of the reverse stock split.

Liquidity

In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements were issued.

As an emerging growth entity, the Company has devoted substantially all of its resources since inception to organizing and staffing the Company, business planning, raising capital, establishing its intellectual property portfolio, acquiring or discovering product candidates, research and development activities for THB001 and other compounds, establishing arrangements with third parties for the manufacture of its product candidates and component materials, and providing general and administrative support for these operations. As a result, the Company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future.

Since its inception, the Company has funded its operations primarily with proceeds from sales of shares of its redeemable convertible preferred stock and most recently with proceeds from the IPO. The Company has incurred recurring losses since its inception, including net losses of $7.4 million and $8.2 million and for the three months ended September 30, 2021 and 2022, respectively and net losses of $13.8 million and $23.7 million for the nine months ended September 30, 2021 and 2022, respectively. As of September 30, 2022, the Company had an accumulated deficit of $71.9 million. To date the Company has not generated any revenues and expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these condensed consolidated financial statements, the Company expects that its existing cash and cash equivalents of $299.5 million as of September 30, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these condensed consolidated financial statements.

COVID-19 Pandemic

The global coronavirus disease 2019 (“COVID-19”) pandemic continues to evolve, and the Company will continue to monitor the ongoing COVID-19 pandemic. The extent of the impact of the ongoing COVID-19 pandemic on the Company’s business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on the Company’s contract development and manufacturing organizations (“CDMOs”), contract research organizations (“CROs”), and other third parties with whom the Company does business, as well as its impact on regulatory authorities and key scientific and management personnel. The ultimate impact of the ongoing COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. The Company’s financial results for the periods ended December 31, 2021 and September 30, 2022 were not significantly impacted by the ongoing COVID-19 pandemic, however, the Company cannot at this time predict the specific extent, duration, or full impact that the ongoing COVID-19 pandemic will have on its financial condition, operations, and business plans for 2022, including the timing and enrollment of patients in its planned clinical trials and other expected milestones of its lead product candidate.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Mar. 31, 2021
Issuance costs	$ 2,300
Series A-2 Redeemable Convertible Preferred Stock
Issuance costs		$ 40
Series A-3 Redeemable Convertible Preferred Stock
Issuance costs		$ 40

Accrued Expenses and Other Current Liabilities

9 Months Ended

Sep. 30, 2022

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

4. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	December 31, 2021		September 30, 2022
Accrued research and development expenses	$	2,685	$	893
Professional fees		450		1,039
Employee compensation and related benefits		752		1,068
Other		2		3
Total accrued expenses and other current liabilities	$	3,889	$	3,003

Net Loss Per Share

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Net Loss Per Share

10. Net Loss Per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share amounts):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2022		2021		2022
Numerator:
Net loss	$	7,381	$	8,205	$	13,827	$	23,665
Net loss attributable to common stockholders, basic and diluted	$	7,381	$	8,205	$	13,827	$	23,665
Denominator:
Weighted-average number of common shares used in net loss per share, basic and diluted		8,159,044		11,827,663		3,994,784		10,451,300
Net loss per share of common stock, basic and diluted	$	0.90	$	0.69	$	3.46	$	2.26


	Three and Nine Months Ended September 30,
	2021		2022
Redeemable convertible preferred stock		29,673,125		—
Options to purchase common stock		394,254		2,542,936
Unvested restricted stock		1,823,080		1,072,054
Total		2,217,334		3,614,989

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Accrued research and development expenses	$ 893	$ 2,685
Professional fees	1,039	450
Employee compensation and related benefits	1,068	752
Other	3	2
Total accrued expenses and other current liabilities	$ 3,003	$ 3,889

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT - USD ($) $ in Thousands	Total	Series A-1 Redeemable Convertible Preferred Stock	Series A-2 Redeemable Convertible Preferred Stock	Series A-3 Redeemable Convertible Preferred Stock	Series B Redeemable Convertible Preferred Stock	Series A-2 Second Tranche	Redeemable Convertible Preferred Stock Series A-1 Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Series A-2 Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Series A-3 Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Series B Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Series A-2 Second Tranche Series A-1 Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Series A-2 Second Tranche Series A-2 Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Series A-2 Second Tranche Series A-3 Redeemable Convertible Preferred Stock	Common Stock	Common Stock Series A-2 Second Tranche	Additional Paid-In Capital	Additional Paid-In Capital Series A-2 Second Tranche	Accumulated Deficit	Accumulated Deficit Series A-2 Second Tranche
Beginning balance at Dec. 31, 2020	$ (18,357)						$ 11,008	$ 7,691	$ 0					$ 1		$ 274		$ (18,632)
Beginning balance, shares at Dec. 31, 2020							12,746,961	6,875,000	0					3,866,138
Issuance of redeemable convertible preferred stock	0					$ 0	$ 1,566		$ 1,982		$ 0	$ 11,785	$ 0	$ 0	$ 0	0	$ 0	0	$ 0
Issuance of redeemable convertible preferred stock, shares							1,223,039		1,953,125		0	6,875,000	0	0	0
Gain on extinguishment of Series A-2 redeemable convertible preferred stock tranche liability	750						$ 0	$ 0	$ 0					$ 0		750		0
Gain on extinguishment of Series A-2 redeemable convertible preferred stock tranche liability, shares							0	0	0					0
Vesting of restricted stock	0						$ 0	$ 0	$ 0					$ 0				0
Vesting of restricted stock, shares							0	0	0					66,837
Stock-based compensation expense	73						$ 0	$ 0	$ 0					$ 0		73		0
Net loss	(2,247)						0	0	0					0		0		(2,247)
Ending balance at Mar. 31, 2021	(19,781)						$ 12,574	$ 19,476	$ 1,982					$ 1		1,097		(20,879)
Ending balance, shares at Mar. 31, 2021							13,970,000	13,750,000	1,953,125					3,932,975
Beginning balance at Dec. 31, 2020	(18,357)						$ 11,008	$ 7,691	$ 0					$ 1		274		(18,632)
Beginning balance, shares at Dec. 31, 2020							12,746,961	6,875,000	0					3,866,138
Stock-based compensation expense														$ 0
Net loss	(13,827)
Ending balance at Sep. 30, 2021	(31,159)						$ 12,574	$ 19,476	$ 1,982					$ 1		1,299		(32,459)
Ending balance, shares at Sep. 30, 2021							13,970,000	13,750,000	1,953,125					4,153,286
Beginning balance at Mar. 31, 2021	(19,781)						$ 12,574	$ 19,476	$ 1,982					$ 1		1,097		(20,879)
Beginning balance, shares at Mar. 31, 2021							13,970,000	13,750,000	1,953,125					3,932,975
Vesting of restricted stock	0						$ 0	$ 0	$ 0					$ 0		0		0
Vesting of restricted stock, shares							0	0	0					136,289
Stock-based compensation expense	65						$ 0	$ 0	$ 0					$ 0		65		0
Net loss	(4,199)	$ 0	$ 0	$ 0										0		0		(4,199)
Ending balance at Jun. 30, 2021	(23,915)						$ 12,574	$ 19,476	$ 1,982					$ 1		1,162		(25,078)
Ending balance, shares at Jun. 30, 2021							13,970,000	13,750,000	1,953,125					4,069,264
Vesting of restricted stock	0						$ 0	$ 0	$ 0
Vesting of restricted stock, shares							0	0	0					84,022
Stock-based compensation expense	137						$ 0	$ 0	$ 0							137		0
Net loss	(7,381)	0	0	0										$ 0		0		(7,381)
Ending balance at Sep. 30, 2021	(31,159)						$ 12,574	$ 19,476	$ 1,982					$ 1		1,299		(32,459)
Ending balance, shares at Sep. 30, 2021							13,970,000	13,750,000	1,953,125					4,153,286
Beginning balance at Dec. 31, 2021	(46,706)						$ 12,574	$ 19,476	$ 33,288	$ 104,846				$ 1		1,534		(48,241)
Beginning balance, shares at Dec. 31, 2021							13,970,000	13,750,000	7,812,501	14,091,686				4,237,290
Vesting of restricted stock	0						$ 0	$ 0	$ 0	$ 0				$ 0		0		0
Vesting of restricted stock, shares							0	0	0	0				84,024
Stock-based compensation expense	450						$ 0	$ 0	$ 0	$ 0				$ 0		450		0
Net loss	(7,784)	0	0	0	$ 0									0		0		(7,784)
Ending balance at Mar. 31, 2022	(54,040)						$ 12,574	$ 19,476	$ 33,288	$ 104,846				$ 1		1,984		(56,025)
Ending balance, shares at Mar. 31, 2022							13,970,000	13,750,000	7,812,501	14,091,686				4,321,314
Beginning balance at Dec. 31, 2021	(46,706)						$ 12,574	$ 19,476	$ 33,288	$ 104,846				$ 1		1,534		(48,241)
Beginning balance, shares at Dec. 31, 2021							13,970,000	13,750,000	7,812,501	14,091,686				4,237,290
Net loss	(23,665)
Ending balance at Sep. 30, 2022	298,422						$ 0	$ 0	$ 0	$ 0				$ 4		370,324		(71,906)
Ending balance, shares at Sep. 30, 2022							0	0	0	0				39,270,140
Beginning balance at Mar. 31, 2022	(54,040)						$ 12,574	$ 19,476	$ 33,288	$ 104,846				$ 1		1,984		(56,025)
Beginning balance, shares at Mar. 31, 2022							13,970,000	13,750,000	7,812,501	14,091,686				4,321,314
Vesting of restricted stock	0						$ 0	$ 0	$ 0	$ 0				$ 0		0		0
Vesting of restricted stock, shares							0	0	0	0				94,740
Stock-based compensation expense	1,159						$ 0	$ 0	$ 0	$ 0				$ 0		1,159		0
Net loss	(7,676)	0	0	0	0											0		(7,676)
Ending balance at Jun. 30, 2022	(60,557)						$ 12,574	$ 19,476	$ 33,288	$ 104,846				$ 1		3,143		(63,701)
Ending balance, shares at Jun. 30, 2022							13,970,000	13,750,000	7,812,501	14,091,686				4,416,054
Vesting of restricted stock	0						$ 0	$ 0	$ 0	$ 0				$ 0		0
Vesting of restricted stock, shares							0	0	0	0				338,488
Stock-based compensation expense	1,006						$ 0	$ 0	$ 0	$ 0				$ 0		1,006		0
Exercise of stock options	107	$ 0	$ 0	$ 0	$ 0									$ 0		107		0
Exercise of stock options, shares		0	0	0	0									13,282
Conversion of convertible preferred stock into common stock upon closing of initial public offering	170,186						$ (12,574)	$ (19,476)	$ (33,288)	$ (104,846)				$ 2		170,184		$ 0
Conversion of convertible preferred stock into common stock upon closing of initial public offering, shares							(13,970,000)	(13,750,000)	(7,812,501)	(14,091,686)				21,967,316
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $2.3M	195,885						$ 0	$ 0	$ 0	$ 0				$ 1		195,884
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $2.3M, shares							0	0	0	0				12,535,000				0
Net loss	(8,205)	$ 0	$ 0	$ 0	$ 0											0		$ (8,205)
Ending balance at Sep. 30, 2022	$ 298,422						$ 0	$ 0	$ 0	$ 0				$ 4		$ 370,324		$ (71,906)
Ending balance, shares at Sep. 30, 2022							0	0	0	0				39,270,140

Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Temporary Equity [Line Items]
Preferred Stock Authorized		49,624,190
Preferred Stock Issued		49,624,187
Preferred Stock Outstanding		49,624,187
Carrying Value		$ 170,184
Liquidation Value		$ 160,970
Common Stock Issuable Upon Conversion		49,624,187
Series A-1 Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		13,970,000
Preferred Stock Issued		13,970,000
Preferred Stock Outstanding		13,970,000
Carrying Value	$ 0	$ 12,574
Liquidation Value		$ 13,970
Common Stock Issuable Upon Conversion		13,970,000
Series A-2 Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		13,750,000
Preferred Stock Issued		13,750,000
Preferred Stock Outstanding		13,750,000
Carrying Value	$ 0	$ 19,476
Liquidation Value		$ 22,000
Common Stock Issuable Upon Conversion		13,750,000
Series A-3 Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		7,812,501
Preferred Stock Issued		7,812,501
Preferred Stock Outstanding		7,812,501
Carrying Value	$ 0	$ 33,288
Liquidation Value		$ 20,000
Common Stock Issuable Upon Conversion		7,812,501
Series B Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		14,091,689
Preferred Stock Issued		14,091,686
Preferred Stock Outstanding		14,091,686
Carrying Value		$ 104,846
Liquidation Value		$ 105,000
Common Stock Issuable Upon Conversion		14,091,686